Dilution from the exercise of share options
First written in FY2022. 12 of 16 entries say "Materialised", first in FY2023-Q2. Latest entry: 2026-09-29.
Slogan moved to the "Worse" side of this theme in 2022, 1 year after the typical company in this theme (2021).
The whole theme swung hardest in 2017: 28 of 54 companies on the "Worse" side.
56 other companies' latest entry also says "Materialised".
- 2026-09-29MaterialisedEarnings
「新株予約権の行使による株式の発行による収入 1,320」
当中間期にも新株予約権の行使に伴う株式発行があり、期末発行済株式数は前期末から2,000株増加している。 - FY2027-H1MaterialisedAnnual report
「Increase/decrease in total number of shares issued 2,000 (Note) This increase resulted from the exercise of stock acquisition rights.」
The total number of shares issued increased by 2,000 shares through the exercise of stock acquisition rights between March and August 2026, with dilution continuing to emerge through the issuance of shares. - FY2026MitigatedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares represented by stock acquisition rights was 236,600, equivalent to 8.54% of the total 2,769,875 shares issued. However, the terms provide for the rights to become exercisable in stages during the exercise period, thereby spreading the impact of dilution.」
The number of potential shares and their percentage of total shares issued declined from 266,500 and 9.69% at the previous fiscal year-end to 236,600 and 8.54%, respectively. Meanwhile, 18,500 shares were issued through the exercise of stock acquisition rights during the fiscal year. - FY2026-H1MaterialisedAnnual report
「Change in total shares issued 11,000 (Note) 1. Increase resulting from the exercise of stock acquisition rights.」
Between March and August 2025, the exercise of stock acquisition rights increased total shares issued by 11,000, followed by a further increase of 7,500 in September 2025. The dilution risk continues to materialise as share issuance. - FY2025WorsenedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares represented by stock acquisition rights was 266,500, equivalent to 9.69% of the total 2,751,375 shares issued. However, the terms provide for the rights to become exercisable in stages during the exercise period, thereby spreading the impact of dilution.」
The issuance and other events relating to the ninth and tenth series of stock acquisition rights increased potential shares to 266,500, or 9.69% of total shares issued, up from 4.35% at the previous fiscal year-end. - FY2025-H1MaterialisedAnnual report
「Change in total shares issued 500 (Note) Increase resulting from the exercise of stock acquisition rights.」
Between March and August 2024, the exercise of stock acquisition rights increased total shares issued by 500, with dilution continuing to materialise as share issuance. - FY2025-Q1WorsenedAnnual report
「At a meeting of its Board of Directors held on 29 May 2024, the Company resolved, pursuant to Articles 236, 238 and 240 of the Companies Act, to issue the ninth series of stock acquisition rights as stock options to its Directors, including Outside Directors, and employees, and issued them on 28 June 2024.」
The Company issued the ninth series of stock acquisition rights covering 152,000 shares to Directors and employees, disclosing new potential shares in addition to dilution from the exercise of existing stock acquisition rights. - FY2024MaterialisedAnnual report
「The increase of 38,800 in the number of common shares issued resulted from the exercise of stock acquisition rights.」
Share issuance through the exercise of stock acquisition rights continued during the fiscal year, increasing total shares issued by 38,800. At fiscal year-end, potential shares totalled 119,500, equivalent to 4.35% of total shares issued. - FY2024-Q3MaterialisedAnnual report
「1 September 2023–30 November 2023 500 shares (Note) Increase resulting from the exercise of stock acquisition rights.」
During the third quarter, the exercise of stock acquisition rights increased total shares issued by 500, followed by a further increase of 2,500 in December 2023. The dilution risk continues to materialise as share issuance. - FY2024-Q2MaterialisedAnnual report
「Between 1 September 2023 and 30 September 2023, the total number of shares issued increased by 500 through the exercise of stock acquisition rights.」
During the second quarter, the exercise of stock acquisition rights increased total shares issued by 800, followed by a further increase of 500 in September 2023 before the submission date. The dilution risk continues to materialise as share issuance. - FY2024-Q1MaterialisedAnnual report
「1 March 2023–31 May 2023 35,000 shares (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights increased total shares issued by 35,000 during the first quarter, with the dilution risk continuing to materialise as share issuance. - FY2023-Q3MaterialisedAnnual report
「Between 1 December 2022 and 31 December 2022, the total number of shares issued increased by 2,900 through the exercise of stock acquisition rights.」
The exercise of stock acquisition rights increased total shares issued by 2,900 during the filing period, with part of the dilution risk continuing to materialise as share issuance. - FY2023-Q2MaterialisedAnnual report
「Between 1 June 2022 and 31 August 2022, the total number of shares issued increased by 2,100 through the exercise of stock acquisition rights.」
The exercise of stock acquisition rights increased total shares issued by 2,100, with part of the dilution risk from potential shares materialising as an actual share issuance. - FY2022First statedAnnual report
「As of the date of submission of this document, the number of potential shares represented by stock acquisition rights was 195,500, equivalent to 7.2% of the total 2,703,075 shares issued. However, the terms provide for the rights to become exercisable in stages during the exercise period, thereby spreading the impact of dilution.」
The Company reports 195,500 potential shares, equivalent to 7.2% of total shares issued, and explains that staged exercise is designed to spread the dilution impact.